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Abstract
BRM is an ATPase component of the SWI/SNF complex that regulates chromatin remodeling and cell proliferation and is considered a tumor suppressor. In this study we
characterized transcripts from the Smarca2 gene that encodes the BRM protein. We found
that the human Smarca2 gene (hSmarca2), like its mouse counterpart (mSmarca2), also
initiated a short transcript from intron 27 of the long transcript. We name the long and
short transcripts as Smarca2-a and Smarca2-b, respectively. Like its human counterpart,
mSmarca2-a also underwent alternative splicing at the 54-bp exon 29. The hSmarca2-b
had two alternative initiation sites and underwent alternative splicing at three different
3’ sites of exon 1 and at exons 2, 3 and/or 5. We identified nine hSmarca2-b mRNA variants that might produce five different proteins. mSmarca2-b also underwent alternative
splicing at exon 3 and/or exon 5, besides alternatively retaining part of intron 1 in exon 1.
Smarca2-b was expressed more abundantly than Smarca2-a in many cell lines and was
more sensitive to serum starvation. Moreover, cyclin D1 also regulated the expression of
both Smarca2-a and Smarca2-b in a complex manner. These data suggest that the functions of the Smarca2 gene may be very complex, not just simply inhibiting cell proliferation, and in certain situations may be elicited mainly by expressing the much less known
Smarca2-b, not the better studied Smarca2-a and its products BRM proteins.
Key words: Alternative splicing, Tumor suppressor gene, BRM, Smarca2, SWI/SNF complex,
Cancer, Cyclin D1

Introduction
Most genes in a eukaryotic genome consist of
exons and introns. During a splicing process, about
91% of a transcript (pre-mRNA) sequence is removed
as introns; the remaining 9% as exons are joined to
form a mature mRNA for protein translation (1).
Transcripts from over 70% of the genes in the human
genome undergo alternative splicing to produce dif-

ferent mature mRNAs (2), which greatly diversifies
the protein products from individual genes. In a disease situation such as cancer that has gene mutations,
even more alternative splicing events may occur because over 14% of disease-causing mutations affect
the splicing process (3,4), in part because the mutations occur at splice sites, as in the case of the BRCA2
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gene (5).
There are quite a few patterns of alternative
splicing, including cassette alternative exons, alternative 5’ splice sites, alternative 3’ splice sites, mutually
exclusive splice sites and retained introns (1). Moreover, one gene can also be transcribed to different
pre-mRNAs by using different promoters and initiation sites, and each pre-mRNA may undergo several
patterns of splicing, which together further increases
the number of mature mRNAs from each individual
gene. A well-studied example is the Drosophila
Down syndrome cell adhesion molecule (Dscam)
gene, which can generate 38,016 mRNA variants by
alternatively splicing its 95 exons (6). Another example is the titin gene that is expressed to, on average,
about 0.5 kg Titin protein in the muscle of an adult
human (7). How the 363 exons of the human titin gene
are alternatively spliced is still largely unknown but
over one million splice variants are estimated (7).
BRM is an ATPase component of the SWI/SNF
complex that regulates chromatin remodeling. It
functions as a gatekeeper of proliferation in cancers
(8) in part by its collaboration with the retinoblastoma
(Rb) protein to repress E2F (9). Most of the known
functions of BRM protein suggest that it may be a
tumor suppressor (10). However, BRM has also been
shown to transactivate the telomerase reverse transcriptase (Tert) gene and further modulate Tert splicing (11), which does not seem to support its tumor-suppressive role because Tert activation is supposed to promote cancer formation and progression.
Possibly, the functions of BRM proteins may be complex and may vary among different situations.
Lost or decreased expression of Smarca2, the
gene encoding the BRM proteins, has been reported in
many cell lines of different types of cancer, which is in
line with its putative role as a tumor suppressor
(10,12-15). The gene silencing is generally considered
to be due to epigenetic mechanisms (14,16), in part
because there has not been any critical genetic change
identified in those cell lines that have lost BRM expression, although loss of heterozygosity in the
Smarca2-containing locus has been reported in some
cancers (17).
Like many other genes, Smarca2 may diversify
its function by yielding multiple mRNA variants. In
the NCBI database, the mouse Smarca2 (mSmarca2)
gene has a long transcript designated herein as
mSmarca2-a and a short transcript coined herein as
mSmarca2-b that is initiated from the intron 27 of the
mSmarca2-a, as illustrated in figure 1. The human
Smarca2 (hSmarca2) also has two mRNA variants but,
unlike the mSmarca2 mRNA variants, they are de-
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rived from alternative splicing at the exon 29, designated herein as hSmarca2-a1 with this exon and
hSmarca2-a2 without this exon (Fig. 1). Reisman et al
mentioned an additional transcription initiation site
that is close to the one that initiates the Smarca2-a (10),
but we are unable to illustrate it in figure 1 because it
is unclear whether this initiation site is identified in
the mouse, human or both species.
In this communication, we report that the long
transcript in the mouse also undergoes alternative
splicing to generate mSmarca2-a1 that contains exon
29, just like its human counterpart. On the other hand,
the hSmarca2 gene also initiates a short transcript,
hSmarca2-b, from two different sites in intron 27 of
hSmarca2-a. This hSmarca2-b undergoes alternative
splicing at three different 3’ sites of exon 1 and at exons 2, 3 and/or 5. These complex patterns of transcription initiation and alternative splicing may engender many different hSmarca2-b mRNA variants,
and we identified nine of them. mSmarca2-b also had
alternative splice variants. Moreover, Smarca2-a and
Smarca2-b can be differentially expressed in different
cell lines and regulated by cyclin D1 and by serum
concentration. These findings suggest that the functions of the Smarca2 gene may be very complex and
may be elicited mainly by expressing the Smarca2-b in
certain situations.

Materials and Methods
Cell lines and cell culture: 168FARN, 4T07, 4T1,
66C14 and 67RN are cell lines established from the
same mouse mammary tumor (18). NMuMG and
HC11 are non-malignant mouse mammary epithelial
cell lines. ND5 and ND11 are malignant clones of
NMuMG cells transformed by cyclin D1 (19). MT-tgfα
or T/M is a cell line established by us from a mammary tumor developed in a female MT-tgfα transgenic
or MT-tgfα/MMTV-c-myc double transgenic mouse,
respectively. H5 and M8 are a pcDNA3.1-hygromycin
empty vector and a pcDNA3.1-c-myc expressing
clone, respectively, of an Ela-myc transgenic mouse
pancreatic cancer cell line (20,21). MCF10A is a
non-malignant human breast epithelial cell line,
whereas MCF7, MDA-MB231, T47D, and SKBR3 are
human breast cancer cell lines. MCF15 is a new human breast cancer cell line in the MCF series (22).
GI101A and its parental GILMmix are human breast
cancer cell lines provided by Dr. JE Price at M.D.
Anderson Cancer Center. AsPC-1, Panc-1, Panc-28,
L3.6pL and MiaCapa-2 are human pancreatic cancer
cell lines. There were many more mouse and human
cell lines that were used in this study but are not listed
here because the related data are not presented. All
the cells were cultured in routine conditions with
http://www.jcancer.org
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DMEM containing 10% serum. The cells were harvested when they reached about 80% confluence, but
for the serum starvation study the medium was
changed to a new one without serum for additional 48
hours of culture before cell harvest.
Retroviral infection: A human cyclin D1 (D1)
cDNA or its K112E mutant (23) tagged with a Flag
sequence at the N-terminus was inserted into a pMIG
retroviral vector that contains an IRES-driven green
fluorescent protein (GFP) sequence after the insert.
These constructs and the empty vector were packaged
in 293T cells and the resulting viruses were used to
infect desired cells, followed by sorting for GFP to
enrich the infected cells.
RT-PCR assay: Total RNA samples were extracted from cells by using TRIzol (Invitrogen; catalog
number: 15596-026), followed by DNase treatment to
remove DNA. Mouse tissues were homogenized with
polytron in a buffer containing protease K (24) before
RNA extraction with TRIzol. RNA samples from
normal human tissues were also purchased from
Clontech (www.clontech.com). The RNAs were reverse transcribed (RT) to cDNA using hexamer primers. Amplification by Polymerase chain reaction
(PCR) was conducted with the forward and reverse
primers listed in table 1.
Table 1: Primer list
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used as reverse primers. The RACE products were
fractionized in agarose gel, and dominant bands were
purified and ligated into a pGEM-T Easy Vector
(Promega, Madison, WI). RT-PCR products were also
cloned in this way. Bacterial clones transformed by
the plasmids were selected and propagated.
DNA sequencing and sequence analysis: The
desired band of PCR products in agarose gel was purified with a DNA purification kit from UltraClean
Gel DNA Extraction Kit (ISC BioExpress, Kaysville,
UT), following the manual. The DNA sample was sent
to Genewiz, Inc. (South Plainfield, NJ) for sequencing.
Plasmid DNA of desired clones from T-A cloning or
5’RACE was also sequenced. DNA sequence analysis
was mainly conducted with DNAStar software.
Western blot assay: Cells were prepared for
protein lysates as described before (25). An equal
amount of proteins was fractioned in 12% SDS-PAGE
and then transferred onto an Immobilon-P Nylon
membrane (Millipore, Bedford, MA). After being
blocked with 5% milk, the membrane was incubated
with a mouse monoclonal (catalog number: sc-166579)
or a rabbit polyclonal (catalog number: sc-28710) BRM
antibody (Santa Cruz Biotech., Santa Cruz, CA) at
1:1000 dilution and then with a corresponding secondary antibody conjugated with a horseradish peroxidase, with three washes between each blocking.
The signal was visualized by luminal-based chemiluminescent substrate (Pierce, Rockford, IL) on X-ray
film (ISC BioExpress, Kaysville, UT).

Results

5’RACE and T-A cloning: Total RNA from
L3.6pL cells was used for a 5’RACE assay with
FirstChoice RLM-RACE Kit (Ambion, Inc. Austin,
TX), following the manual. The hSmarca2R4230 (outer) and hSmarca2R4106 (inner) listed in table 1 were

In this study we analyzed in a systematic manner the transcription of mouse and human Smarca2
gene and the splicing of the transcripts. Because the
NCBI database documents a long and a short transcripts of Smarca2 in the mouse but only the long
transcript in the human, we first determined the alternative splicing of both transcripts in the mouse and
then, based on the information from the mouse, explored whether the short transcript was also expressed in the human and, if yes, whether it underwent alternative splicing as well. Once the mRNA
variants were confirmed by sequencing, bioinformatic
analyses were applied to determine their open reading frames (ORF) and regulation of their expression
by cyclin D1 and serum starvation was explored as
the mechanistic part of the study. The results obtained
were presented below in this logical order.
Alternative splicing of mouse Smarca2-a
Because in the NCBI database hSmarca2-a1 contains the 54-bp exon 29 (Fig. 1A), we wonder whether
this exon also appears in mSmarca2-a or mSmarca2-b.

http://www.jcancer.org
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Using a forward primer at exon 26 (mSmarca2F3855;
table 1) and a reverse primer (mSmarca2R4524) at the
102-bp exon 31 of mSmarca2-a (the exon is numbered
based on hSmarca2-a1), we performed PCR to amplify
the RT products from many mouse tissues and cell
lines. Results from some cell lines are presented in Fig.
1B and 1C, whereas similar data obtained from many
other cell lines or tissues are not shown. Purifying and
then sequencing the bottom band of mSmarca2-a
shown in Fig. 1B revealed that it was the
NM_011416.2 sequence in the NCBI database that
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lacks the 54-bp exon and is thus designated as
mSmarca2-a2 (Fig. 1A). Sequencing the top band revealed that it actually contained two cDNA sequences: one contains the 54-bp exon 29, like the hSmarca2-a1 (Fig. 1A), and is thus designated as mSmarca2-a1 (Supplementary Material: Fig. S1), whereas the
other one is the mSmarca2-a2 lacking this exon. The
mSmarca2-a1 was expressed more abundantly, relative to the mSmarca2-a2, manifested as higher peaks
in the sequence graph (not shown).

Fig 1: Expression of different Smarca2 mRNA variants. A: Illustration of human (h) and mouse (m) Smarca2 mRNA variants documented in the NCBI database, with access number (such as NM_003070.3) provided. Only several exons at the 3’-part for Smarca2-a or the 5’-part for Smarca2-b are shown. Each box indicates an exon with the exon number inside. The figure below a box
indicates the length of that exon in base-pairs (bp). Note that the two human Smarca2 variants differ by the alternative skip of the
54-bp exon 29 and that the two mouse Smarca2 variants are denoted as –a2 or –b2 because they both lack the 54-bp exon, like the
hSmarc2-a2. B: RT-PCR detection of mSmarca2 in H5 and M8 cells with F3855+R4524 primers for mSmarca2-a and F’43+R4524
primers for Smarca2-b. As a negative control, the cDNA template was replaced with water. C: Expression of mSmarca2, detected by
RT-PCR with the same primer sets as in (B), in a panel of mouse breast cancer or non-malignant cell lines (from lanes 1 to 9):
168FARN, 4T07, 4T1, 66C14, 67RN, NMuMG, HC11, T/M and MT-tgfα. D & E: RT-PCR detection of mSmarca2-b in H5 and M8 cells,
with the F’192 and R4524 primers, reveals two (D) or three bands (E) in agarose gel. F: Illustration of the three newly identified
mSmarca2-b mRNA variants confirmed by sequence data, designated as mSmarca2-b3, -b4, and -b10, respectively. Note that all
three variants differ from the mSmarca2-b2 in the NCBI database (A) by lacking the 35-bp exon 3 and that mSmarca2-b3 retains the
54-bp exon 5 that is absent in the mSmarca2-b2. The exon 1 of mSmarca2-b10 retains 408 bp of intron 1.

Alternative splicing of mouse Smarca2-b
Wondering whether the short transcript
mSmarca2-b also undergoes alternative splicing at the

54-bp exon, we used a forward primer (mSmarca2’F192; table 1) located at the 96-bp exon 2 of
mSmarca2-b and the same reverse primer used above
(mSmarca2R4524) to perform PCR with cDNA samhttp://www.jcancer.org
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ples from H5 and M8 cells. The PCR products revealed two bands (Fig. 1D) sometimes but three bands
(Fig. 1E) at other times in agarose gel. Purifying and
then sequencing each of the two bands shown in Fig.
1D revealed that the top band was a variant lacking
the 35-bp exon 3 but retaining the 54-bp exon 5,
whereas the bottom band was a variant lacking both
exons 3 and 5 (Supplementary Material: Fig. S2). We
also purified and sequenced each of the three bands
appearing in Fig. 1E, and found that the top and the
bottom bands were the above two variants, respectively, whereas the middle band contained both of
these two variants and thus was a heterodimer that
sometimes occurs between two similar sequences in
PCR products, according to our experience. We designated the sequence in the NCBI database
(NM_026003.2) (Fig. 1A) that contains the 35-bp exon
3 as mSmarca2-b2 and the two new sequences as
mSmarca2-b3 and -b4, respectively (Fig. 1F), in case
there is a full-length variant mSmarca2-b1 that retains
both exons 3 and 5 as seen in the human (see below).
Identification of human Smarca2-b and its splicing
pattern
Wondering whether the short transcript, i.e.
Smarca2-b, is also expressed in humans, we performed RT-PCR with the forward primer mSmarca2’F43, which is located at exon 1 of mSmarca2-b,
and with the reverse primer mSmarca2R4524 that is
located at exon 7 of mSmarca2-b (table 1). The PCR
products from cDNA samples of multiple human cell
lines or tissues revealed multiple bands in agarose gel.
Results from some cell lines are presented in the
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middle panel of Fig. 2A and 2B, whereas similar data
from many other cell lines and tissues are not shown.
We collectively purified these bands and cloned
them into a TA vector. Cloned cDNA products were
from RNA samples of MCF15 human breast cancer
cells (22), AsPC-1 pancreatic cancer cells, and a commercial RNA sample of normal human pancreas. For
each of these three cell lines and tissue, four to six
plasmid clones were sequenced and the clones from
the same cell line or tissue show different sequences
(table 2).
The sequence results shows that exon 1 has three
different 3’ splice sites, two of which result in a deletion of 7-bp or 41-bp at the 3’end, relative to the third
one (Fig. 2C). Another finding is alternative skip of
the 96-bp exon 2, the 35-bp exon 3, and/or the 54-bp
exon 5. A total of nine mRNA variants were identified
among the 15 plasmid clones sequenced (table 2),
designated as hSmarca2-b1, hSmarca2-b2… hSmarca2-b9, respectively, as illustrated in Fig. 2D (sequences in Supplementary Material: Fig. S3).
The new finding of the alternative skip of the
35-bp exon 3 in mouse Smarca2-b was also observed
in the human. Actually, seven out of nine variants
identified (b3, b4, b5, b6, b7, b8 and b9 vs b1 and b2 in
Fig. 2D) or 12 out of 15 plasmid clones sequenced (table 2) skip this exon, suggesting that the variants
without exon 3 are the majority. Similarly, the variants that skip the 54-bp exon 5 are also dominant,
since six out of nine variants identified (b2, b4, b5, b6,
b7 and b9 vs b1, b3 and b8) or 11 out of 15 plasmid
clones sequenced (table 2) skip this exon. These features are even more obvious when plasmid clones
sequenced for other purposes are counted (see below).

Table 2: Summary of the hSmarca2-b variants with alternative splice at exons 1, 2, 3 and/or 5 and the deduced protein
identified in the normal pancreas as well as MCF15 and AsPC-1 cells.
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Fig 2: Detection of hSmarca2 mRNA variants. A & B: RT-PCR detection of hSmarca2 in several human breast (A) and pancreatic (B)
cancer cell lines or non-malignant (MCF10A) cells with the F3855+R4524 primers for hSmarca2-a and the F’43+R4524 primers for
hSmarca2-b. Note that the hSmarca2-b level is very low but still seems to be visible in MCF7 cells. The separate panel in (A) shows
that the hSmarca2-b, but not the hSmarca2-a, can still be detected in SKBR3 cells when the amount of cDNA template and the PCR
cycles were increased. C: Sequence of the longest (134-bp) exon 1 of the hSmarca2-b determined by 5’RACE. Two transcription
initiation sites are indicated by arrows pointing right. Two additional 3’ splice sites that result in a deletion of 7-bp or 41-bp,
respectively, are indicated by the arrows pointing up. D: Illustration of the nine hSmarca2-b variants confirmed by DNA sequencing.
The size of exon 1 is not indicated because it varies, but the skip of 7-bp or 41-bp is indicated by the shaded 3’ end.

Identification of different transcription initiation
sites of human Smarca2-b
After confirming the existence of hSmarca2-b, we
determined its initiation site by performing 5’RACE
with RNA samples from L3.6pL human pancreatic
cancer cells and with hSmarca2R4230 and hSmarca2R4106 (the number was calculated based on
hSmarca2-a since the initiation site of hSmarca2-b was
unknown) as the reverse primers that are localized at
exon 4, which does not undergo alternative splicing
(Fig. 2D). Sequencing five plasmid clones of the
5’RACE products identified two initiation sites that
were nine nucleotides apart in intron 27 of hSmar-

ca2-a (Fig. 3C). The sequence results also revealed the
7-bp deletion from the 3’-end of exon 1 and the skip of
exon 3 identified by the above described TA cloning
(sequences in Supplementary Material: Fig. S3). Thus,
a random combination of the two alternative initiation
sites and the three 3’ alternative splice sites of exon 1
might, theoretically, result in a longest exon 1 of
134-bp and a shortest exon 1 of 84-bp (Fig. 2C). We
have not yet identified the 84-bp exon 1 but it may
exist in our 5’RACE products. Mathematically, two
different transcription initiation sites, three different
3’ alternative splice sites of exon 1, and alternative
skips of exons 2, 3 and 5 may result in 48 (2x3x2x2x2)

http://www.jcancer.org
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different hSmarca2-b variants, although we have only
identified nine of them.
Expression of Smarca2-a and Smarca2-b in various
cell lines
We have determined the expression levels of
Smarca2-a in many cell lines but here we only describe those data that are discrepant from or absent in
the literature. SKBR3 human breast cancer cells were
reported to express relatively high level of BRM proteins (12), but we were not able to detect hSmarca2-a
in this cell line (Fig. 2A). On the other hand, we found
that the Smarca2-a level in 4T07 mouse breast cancer
cells (Fig. 1C) and MiaPaca2 human pancreatic cancer
cells (Fig. 2B) was very low or undetectable. Moreover, we detected hSmarca2-a in Panc-1 human pancreatic cancer cells (Fig. 2B).
The short transcript Smarca2-b was expressed
abundantly in most mouse and human cell lines and
tissues. Smarca2-b was still readily detectable in some
cell lines wherein the level of Smarca2-a was very low
or undetectable, such as in 4T07 and MiaCapa2 cells
(Fig. 1C and 2B). In SKBR3 cells, hSmarca2-b could be
detected when the number of PCR cycles or the
amount of cDNA template was increased, although
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the hSmarca2-a was still undetectable (Fig. 2A).
However, there still were some cell lines such as
HC11, MCF7 and T47D wherein the Smarca2-a level
was detected abundantly but the level of the Smarca2-b was very low (Fig. 1C and 2A).
Bioinformatic analyses of ORF of hSmarca2-a and
hSmarca2-b
In the NCBI database, hSmarca2-a1 and hSmarca2-a2 encode only a protein of 1590 amino acids (aa)
and 1572 aa, respectively. However, ORF analyses
with DNAStar software identifies a total of 48 ATG
(AUG in mRNA) translation start codons in hSmarca2-a, each of which encodes an ORF longer than 100
aa but all the ORFs are in the same frame and end at
the TGA (UGA in mRNA) translation stop codon at
the 4872-4875th nucleotides (nt) (table 3). hSmarca2-a2
has the same 48 ATGs but the stop codon occurs earlier (at the 4818-4820th nt TGA), because of the lack of
the 54-bp exon 29, which makes the last (the shortest)
ORF different from their counterparts in hSmarca2-a1
(table 3). The 48 ORFs in hSmarca2-a1 encode proteins
that range from 1590 to 119 aa, which, if expressed,
are estimated at about 181 kD to 13 kD on a western
blot.

http://www.jcancer.org
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Fig 3: Illustration of deduced open reading frame (ORF) of hSmarca2-b mRNA variants. Every other exon is shaded to show the
length of each exon and the boundary of neighbor exons. The number of exon (E) is indicated at the left margin. There are two
putative ATG translation start codons, located in exons 2 and 4, respectively. No matter whether exon 1 is initiated from the A1 or
A2 site (arrows pointing right) or has or not a 7- or 41-bp deletion at its 3’-end, it does not affect ORF. Those variants that lack exon
2 have only one ORF starting from ATG2 at exon 4 and ending at the only TGA stop codon in exon 10. A: In those variants that lack
the 35-bp exon 3, the ATG1 and ATG2 are in the same ORF, which ends at the TGA in exon 10 as well. Thus, the proteins starting
from ATG1 have additional 40 amino acids (aa) at the N-terminus compared with those starting from ATG2, whereas those variants
retaining the exon 5 have an 18-aa insert (in box). B: In those variants retaining the 35-bp exon 3, ATG1 starts a protein that ends
at a TGA in exon 4, thus having only 98 aa. The sequence of its first 31 aa encoded by exon 2 is identical to the corresponding part
of those proteins that are also started from ATG1, whereas the remaining 67 aa constitute a sequence that is different from any
part of BRM-related proteins, due to the frame-shift caused by the insert of exon 3. Only ATG2 starts the BRM-related proteins. C:
Illustration of the BRM and related proteins, with the variants that may produce the protein indicated in brackets. The boxes that
are in the same format and vertically aligned at the same position represent identical sequence, with open box as BRM or BRM
related sequence and small grey box representing the 18 aa encoded by the 54-bp exon that may be alternatively skipped. The two
BRM proteins differ by alternative skip of 18 aa. Note that the 294-aa and 276-aa proteins share the first 31 aa (slashed box) with
the 98-aa peptide but differ from the 254-aa and 236-aa proteins by this 31-aa sequence. The remaining 67 aa (checkered box) of
the 98-aa peptide does not exist in any other protein.
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Table 3: Analysis of open reading frame of human hSmarca2-a1

ORF analysis also shows that those hSmarca2-b
variants (b3, b4, b6 and b7 shown in Fig. 2D) that lack
exon 3 may be translated from two ATG translation
start codons located at exons 2 and 4, respectively
(Fig. 3A). These two ATGs are within the same frame
that ends at a TGA stop codon in exon 10; the proteins
starting from ATG1 have additional 40 aa at the
N-terminus compared with those starting from ATG2.
Alternative skip of the 54-bp exon 5 deletes 18 aa from
these proteins (Fig. 3A). However, in those variants
that retain exon 3 (b1 and b2 shown in Fig. 2D), the
two different ATGs start different ORFs because exon
3 causes a frame-shift (Fig. 3B). The protein starting
from ATG1 at exon 2 will end at a TGA in exon 4,
resulting in a 98-aa short peptide (Fig. 3B). The proteins starting from ATG2 still end at the second TGA
in exon 10 and may have an alternative deletion of 18
aa because of the skip of exon 5, just like those proteins from the variants without exon 3. Skip of exon 2
in certain variants (b5, b8 and b9 in Fig. 2D) also deletes the ORF starting from ATG1 without creating
any new ORF, and thus has only one ORF starting
from ATG2 (Fig. 3A and 3B).
The above situations of hSmarca2-b variants, i.e.
two different ATGs in the absence of exon 3, the first
ATG in the presence of exon 3 that causes an early
translation termination, and the alternative skip of
exon 5, together can result in five different proteins
(Fig. 3C). Four of the five belong to the BRM family
and contain 294, 276, 254, and 236 aa, with a calculated molecular weight of 33731.76, 31733.55, 29490.84
and 27492.64 Daltons, respectively, much smaller than
the BRM proteins derived from the hSmarca2-a1
(181278.65 Daltons) or the hSmarca2-a2 (179280.45
Daltons). Moreover, the second ATG is in the same
ORF of hSmarca2-a. Therefore, the 294-aa and 276-aa
proteins that are translated from the first ATG have
the same C-terminal sequence as the hSmarca2-a1 and

hSmarca2-a2 proteins, whereas the 254-aa and 236-aa
proteins translated from the second ATG are identical
to a C-terminal part of the hSmarca2-a1 or hSmarca2-a2 derived BRM proteins (Fig. 3C). The 98-aa
short peptide, which is translated from the first ATG
of the variants containing exon 3 (b1 and b2), is calculated as 11597.91 Daltons. Its first 31-aa sequence
encoded by exon 2 is identical to the corresponding
part of the 294-aa and 276-aa proteins (Fig. 3C),
whereas the remaining sequence of 67 aa differs
completely from any part of BRM or BRM-related
proteins, due to the frame-shift caused by exon 3.
Small BRM-immunoreactive proteins on western
blot
We performed western blot assay using a mouse
monoclonal antibody (sc-166579) and a rabbit polyclonal antibody (sc-28710) that were raised against the
1531-1586th aa of hSmarca2-a1, a region shared with
Smarca2-b. Both antibodies identified several bands
between 24-35 kD and a band slightly higher than 40
kD in cell lines of human and mouse origins. Data
from some of the cell lines were shown in Fig. 4. These
antibodies also recognized several other bands larger
than 50 kD or smaller than 24 kD (data not shown).
The identities of these small BRM-immunoreactive
proteins are unclear. The BRM proteins of about 180
kD fractioned in a much lower percentage (6%) PAGE
were detected only weakly (data not shown), in
strong contrast to the high abundance of the much
smaller proteins shown in Fig. 4.
Effects of cyclin D1 and serum starvation on
Smarca2 expression
We had previously transformed NMuMG
mouse
mammary
epithelial
cells
with
a
pcDNA3.1neo-cyclin D1 (D1) construct and established the D1 expressing, malignant ND5 and ND11
clones (19). ND5 and ND11 cells showed a dramatic
http://www.jcancer.org
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decrease in the levels of both mSmarca2-a and
mSmarca2-b, compared with the parental NMuMG
non-malignant cells (Fig. 5A). Smarca2-b was still detectable in ND11 clone, but its splicing was changed
as evidenced by different patterns of bands on agarose gel between ND11 and NMuMG cells (Fig. 5A).
Interestingly, ND11 cells showed an additional band
at a higher molecular weight (arrow in Fig. 5A).
Cloning this band to a TA vector followed by sequencing some plasmids revealed that it was an alternative splice variant that retained 408 bp of intron 1
at the 3’ end of exon 1 (Supplementary Material: Fig.
S2). This variant, which lacks exons 3 and 5 as well,
was also expressed at a low abundance in some other
mouse cancer cell lines (data not shown). We name
this variant “mSmarca2-b10” in case similar retention
of intron 1 may later be identified in human Smarca2-b, although not yet by now.
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Fig 4: Western blot assays show that a rabbit (left panel) and a
mouse (right panel) BRM C-terminal antibodies recognize several proteins in the lysates from a mouse (4T1) and several
human cancer cell lines. Note that several proteins between
24-35 kD are recognized by both antibodies, in addition to a
protein slightly higher than 40-kD. The same membrane was
stripped and re-blotted with β-actin to show the protein
loading, although no attempt is made to compare the expression levels among the four unrelated cell lines.

Fig 5: Effect of cyclin D1 (D1) and serum starvation on Smarca2 expression. A: Two malignant clones (ND5 and ND11) of NMuMG cells
transformed by stable expression of a pcDNA3.1-D1 construct show dramatic decreases in the levels of mSmarca2-a and mSmarca2-b detected by RT-PCR, compared with the parental NMuMG cells. ND11 cells also manifest a changed pattern of different
mSmarca2-b variants and express a variant at a high molecular weight (arrow). B: Comparison of the MCF7 cells infected with a
retrovirus containing a Flag-D1 construct (D1), a Flag-K112E mutant (KE) or the empty vector (V) shows that D1 dramatically
decreases the level of hSmarca2-a but the KE mutant attenuates this effect of D1. C, D and E: Effect of serum starvation and
retroviral infection with D1 or its K112E mutant on the levels of hSmarca2-a and hSmarca2-b, detected by RT-PCR, in MDA-MB231
(C), L3.6pL (D) and AsPC-1 (E) cells. F: Illustration of how serum and D1 regulate the expression and splicing of Smarca2-a and
Smarca2-b. Serum derived growth stimuli utilize some transcription factors (TFx) to activate or repress the promoter region (grey
box) and the intron 27 (that is also the promoter of Smarca2-b) of the Smarca2 gene (black box). D1, which also acts as a downstream effector of serum, binds to some other transcription factors (TFy) to activate or repress these promoter regions, but
whether CDK4 or CDK6 is involved is unclear. The pre-mRNA of Smarca2-a is spliced alternatively to the -a1 or -a2 variants while the
Smarca2-b pre-mRNA to -b1, -b2… or -b9. These splicing processes may be regulated by serum via D1 or via other splice factors. The
effect of D1 on splicing is more evident in a chronic situation as seen in D1 transformed ND11 clone of NMuMG cells, but whether
CDK4 or CDK6 is involved remains elusive.
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As shown in Fig. 5B, ectopic expression of D1
decreased the Smarca2-a level in MCF7 cells while the
Smarca2-b level remained undetectably low under the
same condition as seen in the vector infected cells.
One major function of D1 is to activate Cyclin Dependent Kinase-4 (CDK4) or -6 (CDK6), but a single
nucleotide mutation of D1 that changes the 112th
amino acid (K112E) abolishes its activity to activate
these CDKs (23). Interestingly, infection of MCF7 cells
with a retroviral K112E mutant had only a mild effect
on hSmarca2-a (Fig. 5B), indicating that down regulation of hSmarca2-a by D1 largely depends on its activation of CDK4 or CDK6. In MDA-MB231 human
breast cancer cells, however, D1 decreased Smarca2-b
while affecting Smarca2-a only mildly, if at all, when
the cells were cultured with 10% serum (Fig. 5C).
K112E mutation also decreased the effect on Smarca2-b, again suggesting its dependence of CDK4 or
CDK6 (Fig. 5C).
Like in MDA-MB231 cells, ectopic D1 in L3.6pL
cells significantly down regulated Smarca2-b without
affecting Smarca2-a (Fig. 5D). However, in AsPC-1
human pancreatic cancer cells, ectopic D1 slightly
induced Smarca2-b without significantly affecting
Smarca2-a when the cells were cultured with 10%
serum (Fig. 5E).
Deprival of MDA-MB231 cells from serum in
culture for 48 hours dramatically decreased the level
of Smarca2-b without affecting Smarca2-a (Fig. 5C).
However, serum starvation together with ectopic D1,
but not its K112E mutant, could significantly decrease
the Smarca2-a level when compared with the empty
vector expressing counterparts, while the Smarca2-b
level remained inhibited by serum starvation in D1 or
K112E expressing MDA-MB231 cells (Fig. 5C). L3.6pL
cells showed a similar decrease in Smarca2-b, but not
in Smarca2-a, in response to serum starvation (Fig.
5D). However, unlike in MDA-MB231 cells, serum
starvation with a concomitant D1 expression was still
unable to significantly change the level of Smarca2-a
in L3.6pL cells (Fig. 5D). In opposite to MDA-MB231
and L3.6pL, AsPC-1 cells showed a significant induction of both Smarca2-a and Smarca2-b in response to
serum starvation (Fig. 5E). Interestingly, D1 expression attenuated the induction of Smarca2-a by serum
starvation, although D1 alone was not able to significantly inhibit Smarca2-a in the presence of 10% serum
(Fig. 5E). D1 did not seem to markedly affect Smarca2-b in AsPC-1 cells wherein Smarca2-b seems to be
more abundantly expressed than Smarca2-a.

Discussion
Splicing of mSmarca2-a and expression of hSmarcar2-b
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The first new finding of our study is that the long
transcript in the mouse (mSmarca2-a) also undergoes
alternative splicing at the 54-bp exon 29 to produce
the -a1 and -a2 variants as seen in the human whereas
the human Smarca2 gene also expresses the short
transcript, i.e. hSmarca2-b, just like its mouse counterpart. Actually, we identified two transcription initiation sites for hSmarca2-b in the intron 27 of the
gene. Another novel finding is that hSmarca2-b can be
alternatively spliced at three different 3’ sites of exon 1
and at exons 2, 3 and 5. These complex patterns of
alternative splicing, together with alternative transcription initiations, may produce 48 different
hSmarca2-b mRNA variants, although we have only
confirmed nine of them. Thus, in both human and
mouse, the Smarca2 gene is expressed to a long
(Smarca2-a) and a short (Smarca2-b) transcripts; both
transcripts undergo alternative splicing, especially the
short one.
Ratios within or among Smarca2-a and Smarca2-b
variants
Of the two Smarca2-a variants in both mouse
and human, Smarca2-a2 that lacks the exon 29 is expressed at a higher amount in most human and
mouse cell lines we studied, relative to Smarca2-a1,
since the bottom band of the Smarca2-a duplex in
agarose gel is dominant in most cases (Fig. 1B, 1C, 2A
and 2B). Skip of this 54-bp exon seems to be prevailing
among Smarca2-b variants as well. Therefore, we intend to consider that this exon appears only as a variation whereas the wild type forms of the long and
short mRNAs do not contain this exon. Under what
condition this exon appears is intriguing but remains
to be determined.
One of the surprising findings is that Smarca2-b
is detected more abundantly than Smarca2-a in many
cell lines, suggesting that the short transcript may be
expressed at a higher level in many cases. Therefore, it
may be Smarca2-b, not the much better studied BRM
proteins translated from Smarca2-a, that better represents the function of the Smarca2 gene. Of the many
cell lines studied, MCF7 and T47D breast cancer cells
and HC11 mammary epithelial cells are exceptions, as
they show the opposite, i.e. a high level of Smarca2-a
but a low level of Smarca2-b. Why these exceptions
only occur to cell lines derived from mammary epithelium is unclear, probably just fortuitous.
Decristofaro et al report that Panc-1 cells are
negative for BRM protein (12) whereas Rosson et al
detect relatively high levels of Smarca2-a mRNA and
BRM protein in this cell line (15). Like Rosson et al, we
detect Smarca2-a mRNA in Panc-1 cells as well. On
the other hand, we cannot detect Smarca2-a in SKBR3
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cells although DeCristorfard et al detect BRM protein
in this cell line (12). Silencing of the Smarca2 gene is
generally considered to be due to epigenetic mechanisms (26-28). The same cell lines in different investigators’ laboratory may differ in the degree of epigenetic silencing, since epigenetic control such as histone deacetylation can be changed readily. This may
be a reason for the discrepant data on the expression
status of Smarca2 in Panc-1 and SKBR3 cells observed
by different investigators. If so, we may be able to
control the behaviors of cancer cells by regulating
epigenetic control of the Smarca2 gene, which may
have a potential in clinical use eventually.
Complex ORFs encoded by various Smarca2-b variants
The complexity of human Smarca2-b occurs not
only at the mRNA level but probably also at the protein level, because our bioinformatic analysis identifies two first ATG translation start codons that may or
may not be in the same ORF, depending on whether
the variants contain the 35-bp exon 3. Moreover, alternative skip of the 54-bp exon 5 also results in an
in-frame deletion of 18 aa. These ORFs encode four
different BRM-related proteins with 294, 276, 254 or
236 aa, respectively, in addition to a 98-aa short peptide. In the mouse, mSmarca2-b3 and mSmarca2-b4
encode a 294-aa and a 276-aa protein, respectively,
whereas the mSmarca2-b10 may utilize another ATG
at the end of exon 1, which adds two more amino acids to the N-terminus of mSmarca2-b4, thus producing a 278-aa protein.
The 98-aa peptide encoded by hSmarca2-b1 and
-b2 that contain the 35-bp exon 3 is of interest, if it is
really expressed. Because the sequence of its first 31 aa
is identical to the corresponding part of the 294-aa and
276-aa proteins (Fig. 3C), it may be considered a
member of the BRM family. However, this 31-aa sequence does not exist in BRM or in the 254-aa and
236-aa proteins, and the remaining sequence of 67 aa
also differs completely from any part of BRM or BRM
related proteins. Therefore, the nature of this 98-aa
peptide is uncertain. It needs to be pointed out that
the only Smarca2-b mRNA (NM_026002.2) documented in the NCBI database is a mouse sequence
that contains the 35-bp exon 3, and its ORF starts from
ATG1 in exon 2 and stops earlier, encoding only 72 aa,
not 98 aa. The NCBI database shows only the 236-aa
protein (NP-080279.1) without documenting this 72-aa
peptide, probably because it is too short. It also needs
to be mentioned that the variants which contain the
35-bp exon 3 occur only as relatively rare events in
both human and mouse in our study. Therefore, the
NM_026002.2 sequence in the NCBI database is
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somewhat misleading as it does not represent the
majority. In other words, this 35-bp exon should be
considered as an extra one that appears only in minor
variants, not in the wild type forms, of hSmarca2-b.
The 254-aa and 236-aa proteins are encoded by
the variants that lack exon 2 (b5, b8 and b9) or the
variants containing exon 3 (b1 and b2). The possible
existence of these proteins somewhat puzzles us because the 254-aa or 236-aa sequence is part of the BRM
protein translated from Smarca2-a1 or Smarca2-a2,
respectively, as illustrated in Fig. 3C. One of the possibilities is that cells may sometimes prefer a simplified or specified function by the C-terminal part of
BRM proteins over the more complex functions by the
full-length BRM. The 294-aa and 276-aa proteins encoded by the variants lacking exon 3 but retaining
exon 2 (b3, b4, b6 and b7) contain the 31-aa sequence
at the N-terminus that does not exist in BRM, thus
sharing some functions with BRM on one hand and
with the 98-aa peptide on the other. Therefore, these
proteins may be a special group of the BRM family
and their existence may be meaningful.
Mechanisms for the appearance of small BRM immunoreactive proteins
Using two BRM C-terminal antibodies, we show
for the first time western blot data of multiple proteins
of 24-35 kD, which may be 1) degraded or proteolyzed
products of the 180-kD BRM proteins, 2) proteins that
are irrelevant to Smarca2 but immunoreactive to the
BRM C-terminal antibodies, i.e. nonspecific bands on
the blot, 3) Smarca2-b proteins as they are within the
estimated molecular weights, or 4) Smarca2-a proteins
translated from some of the 48 in-frame ATGs (AUG
is referred to as ATG herein to abide to NCBI database
that presents mRNA as DNA sequence, including the
Smarca2 mRNA variants). The first possibility is less
likely because the 180-kD BRM proteins are detected
much less abundantly compared with the 24-35 kD
proteins and western blots of β-actin and other proteins (data now shown) confirm the high quality of
the protein preparation without obvious degradation.
The second or third possibility needs to be determined by more studies. If Smarca2-b proteins exist,
each Smarca2-b mRNA variant needs to be causally
linked to one or several specific bands on the western
blot. Cloning the full-length cDNA of various Smarca2-b variants that encode different ORFs and raising
the corresponding antibodies are prerequisites for this
line of work, which are tedious and thus beyond this
communication. The fourth possibility is of interest as
this type of situation is rarely discussed. Generally
speaking, some of the in-frame ATGs in many genes,
like the 48 in-frame ATGs of hSmarca2-a, may be
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functional via a non-classical cap-dependent or even
cap-independent mechanism of protein translation,
including leaky scanning, reinitiation, and IRES (internal ribosome entry site) (29-31). In the case of IRES,
whether an in-frame ATG is functional depends in a
large part on ITAFs (IRES trans-acting factor) expression of which varies among different cells or cellular
situations (32,33). For instance, an IRES existing in the
exon 1 of the c-myc oncogene is 20-fold more active in
Hela cells than in MCF7 cells (34). In silico analyses
suggest that up to 10% of cellular genes contain IRES
(33), although it remains to be determined whether
Smarca2 mRNAs encompass an IRES. Besides IRES,
some relative upstream ATGs may be used as “upstream ATGs” to control translation from the ATGs at
their downstream via a leaky scanning or reinitiation
mechanism (30,31). By using these non-classical
cap-dependent or even cap-independent translation
mechanisms, cells can regulate mRNA decay or
translation efficiency or can produce different protein
isoforms that differ in the N-terminus and thus in
some functions (29-31,35).
Regulation of Smarca2 expression by D1 and serum
Few factors have been identified that regulate
the expression of Smarca2, especially the Smarca2-b.
Serum starvation inhibits cell growth while D1 accelerates it, both via the pRb-E2F pathway. Moreover, D1
is known to act as a sensor of cells to deliver extracellular growth signals, such as those derived from
serum, to the cell cycle machinery (Fig. 5F) (36,37). For
these reasons, we originally anticipated that serum
starvation should induce Smarca2 whereas D1 should
inhibit it, since BRM is considered to inhibit cell proliferation by mediating the pRb-E2F pathway (8,9).
We indeed observe an induction of hSmarca2-a by
serum starvation in AsPC-1 cells and an inhibition of
hSmarca2-a by D1 in MCF7 cells as anticipated. Unexpectedly, however, serum starvation does not induce hSmarca2-a in MDA-MB231 and L3.6pL cells
whereas D1 alone does not inhibit it in AsPC-1,
MDA-MB231 and L3.6pL cells. More surprisingly,
although serum starvation significantly changes the
levels of Smarca2-b in all three cell lines studied (Fig.
5C, 5D and 5E), these cell lines actually respond quite
differently and even oppositely. Obviously, the short
transcript is more sensitive to serum-derived factors
and thus may be a more important regulator than the
Smarca2-a for cell cycle progression, which may be
why Smarca2-b is more abundantly expressed than
Smarca2-a in many cell lines. Nevertheless, these unexpected results suggest a complex regulation of
Smarca2 by serum and D1 and the complexity may
occur at two levels: 1) There may be many genes other
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than D1 that also act as downstream effectors of serum-derived factors to control cell growth by regulation of Smarca2 and these genes show different patterns of changes in different cell lines. 2) D1 per se utilizes multiple mechanisms to regulate Smarca2 expression and splicing (Fig. 5F). As reviewed by two of
us recently (36,37), D1 functions via three different
mechanisms, i.e. a) binding to CDK4/6 to form a
holoenzyme to phosphorylate pRb or other substrates,
b) forming a complex with CDK4/6 without involving their kinase activity, or c) acting via a
CDK4/6-independent mechanism. The third mode of
action has so far been observed only in regulation of
genes’ transcription, which is achieved by binding of
D1 to some transcriptional factors (Fig. 5F) such as
steroid hormone receptors. Few, if any, of these transcriptional regulations involve CDK4/6, to our
knowledge. For this reason, it is surprising that the
K112E mutant that cannot activate CDK4/6 is not as
effective as the wild type D1 in regulation of
Smarac2-a and Smarca2-b mRNA levels, as it implies
the involvement of these CDKs. More studies are
needed to further determine whether the effects of D1
on the expression of Smarca2-a or Smarca2-b occur at
the transcriptional level.
Although the above discussed short-term or
temporary effects of D1 on Smarca2 expression are
somewhat less evident and different among the retrovirus infected MCF7, MDA-MB231, L3.6pL and
AsPC-1 cells, two clones (ND5 and ND11) of D1
transformed NMuMG cells consistently show that the
chronic effects of D1 are dramatic decreases in both
Smarca2-a and Smarca2-b expression or altered
splicing pattern of Smarca2-b. Whether and how D1
plays a role in RNA splicing is an interesting question
that has rarely been studied (Fig. 5F), but it has been
reported that D1 regulates splicing of fibroblast
growth factor 1 receptor (38) and D1b, a splice variant
of D1, utilizes a critical splice factor ASF/SF2 as a
downstream effector to regulate splicing (39). These
chronic effects seen in ND5 and ND11 cells are likely
to be indirect events mediated by other genes, although whether CDK4 or CDK6 is involved remains
elusive (Fig. 5F). Nevertheless, these effects not only
dovetail with the notion that the Smarca2-a products
BRM proteins are tumor suppressors but also further
suggest that some of the Smarca2-b splice variants
may be tumor suppressive as well.

Conclusions
In summary, mSmarca2-a also engenders two
alternative splice variants with or without exon 29,
just like hSmarca2-a, whereas the hSmarca2 gene
produces the short transcript hSmarca2-b as well, just
http://www.jcancer.org
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like its mouse counterpart. Nine hSmarca2-b mRNA
variants are identified and many more anticipated,
due to two alternative initiation sites as well as alternative splicing at three different 3’ splice sites of exon
1 and at exons 2, 3 and 5. mSmarca2-b also undergoes
alternative splicing at exon 3 and/or exon 5, besides a
retention of part of intron 1 by exon 1. Some of the
hSmarca2-b mRNA variants may encode two different ORFs, which together may produce five different
proteins. The expression of Smarca2-a and Smarca2-b
may be regulated by serum concentration and by D1
in a complex manner, and Smarca2-b is expressed
more abundantly than Smarca2-a in many cell lines.
These complex patterns of transcription initiation,
expression regulation, and alternative splicing collectively suggest that in some situations the functions of
the Smarca2 gene may be very complex, not just
simply inhibiting cell proliferation or tumor formation, and be exerted mainly by expressing the short
transcript Smarca2-b.

Supplementary Material
Fig. S1: Sequence of the region between exon 26 and
exon 31 of the mSmarca2-a1 cDNA. Fig. S2: Part of the
sequences of the three novel mSmarca2-b variants.
Fig. S3: Sequences of the nine hSmarca2-b variants
and two of the original 5’RACE sequences.
http://www.jcancer.org/v02p0386s1.pdf
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